Começar
ReutersReuters

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

RefinitivMenos de 1 minuto de leitura
CYBN

Cybin Inc CYBN:

  • CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

Ações CanadensesAções EUAReuters
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Entrar ou criar uma conta gratuita para ler essa notícia

Mais notícias de Reuters